MCID: CRC006
MIFTS: 55

Carcinoid Syndrome

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Carcinoid Syndrome

MalaCards integrated aliases for Carcinoid Syndrome:

Name: Carcinoid Syndrome 52 58 17 32
Malignant Carcinoid Syndrome 58 71
Carcinoid Tumor 52 71
Carcinoid Tumor No Icd-O Subtype 71
Carcinoid Tumor Syndrome 52
Carcinoid Tumors 42

Classifications:

Orphanet: 58  
Rare endocrine diseases


Summaries for Carcinoid Syndrome

NIH Rare Diseases : 52 Carcinoid syndrome refers to a group of symptoms that are associated with carcinoid tumors (rare, slow-growing tumors that occur most frequently in the gastroinestinal tract or lungs). Affected people may experience skin flushing, abdominal pain, diarrhea, difficulty breathing, rapid heart rate, low blood pressure, skin lesions on the face (telangiectasias ), and wheezing . In later stages, carcinoid syndrome may damage the heart valves, resulting in symptoms of congestive heart failure . The condition occurs when the carcinoid tumor secretes serotonin or other chemicals into the bloodstream. Only 10% of people with carcinoid tumors develop carcinoid syndrome; most have advanced stage carcinoid tumors that have spread to the liver. Treatment generally involves addressing the underlying carcinoid tumor and medications to alleviate symptoms.

MalaCards based summary : Carcinoid Syndrome, also known as malignant carcinoid syndrome, is related to appendix carcinoid tumor and pulmonary blastoma. An important gene associated with Carcinoid Syndrome is SDHD (Succinate Dehydrogenase Complex Subunit D), and among its related pathways/superpathways are Relaxin signaling pathway and Neuroscience. The drugs Oxaliplatin and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and liver, and related phenotypes are episodic abdominal pain and protracted diarrhea

MedlinePlus : 42 Carcinoid tumors are rare, slow-growing cancers. They usually start in the lining of the digestive tract or in the lungs. They grow slowly and don't produce symptoms in the early stages. As a result, the average age of people diagnosed with digestive or lung carcinoids is about 60. In later stages the tumors sometimes produce hormones that can cause carcinoid syndrome. The syndrome causes flushing of the face and upper chest, diarrhea, and trouble breathing. Surgery is the main treatment for carcinoid tumors. If they haven't spread to other parts of the body, surgery can cure the cancer.

Wikipedia : 74 Carcinoid syndrome is a paraneoplastic syndrome comprising the signs and symptoms that occur secondary... more...

Related Diseases for Carcinoid Syndrome

Diseases related to Carcinoid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 829)
# Related Disease Score Top Affiliating Genes
1 appendix carcinoid tumor 33.9 SYP ENO2 CHGA
2 pulmonary blastoma 31.8 SYP SST CHGA CALCA
3 carcinoid tumors, intestinal 31.7 SYP SST MEN1 ENO2 CHGA
4 goblet cell carcinoid 31.4 ENO2 CHGA
5 serotonin syndrome 31.1 SST PYY MEN1 IFNA2 HTR3A GHRH
6 atrophic gastritis 31.1 SST MEN1 CHGA
7 diarrhea 30.8 SST PYY HTR3A CALCA
8 horseshoe kidney 30.6 SYP ENO2 CHGA
9 gastrinoma 30.6 SST MEN1 CHGA
10 small cell carcinoma 30.6 SYP ENO2 CHGA CALCA
11 ileus 30.6 SST NTS CALCA
12 adenoma 30.5 SST MEN1 IGF1 CHGA
13 lung benign neoplasm 30.5 SYP ENO2 CHGA
14 conn's syndrome 30.5 SST MEN1 IGF1 GHRH CHGA
15 pituitary tumors 30.3 SST MEN1 IGF1
16 large cell neuroendocrine carcinoma 30.2 SYP ENO2 CHGA
17 glucagonoma 30.2 SST CHGA
18 pancreatic somatostatinoma 30.2 SST CALCA
19 ectopic cushing syndrome 30.2 SYP SST
20 ampulla of vater neoplasm 30.2 SYP SST ENO2 CHGA
21 hyperthyroidism 30.1 SST IGF1 CALCA
22 middle ear adenoma 30.1 SYP ENO2 CHGA
23 tubular adenocarcinoma 30.0 SYP ENO2 CHGA
24 insulin-like growth factor i 30.0 SST IGF1 GHRH
25 pain agnosia 30.0 NTS HTR3A CALCA
26 leptin deficiency or dysfunction 30.0 PYY NPY IGF1
27 pituitary adenoma 30.0 SST MEN1 IGF1 GHRH CHGA
28 rectum neuroendocrine neoplasm 29.9 SYP SST
29 hyperprolactinemia 29.9 SST IGF1 GHRH
30 insulinoma 29.9 SST MEN1 CHGA
31 mediastinal cancer 29.9 SYP ENO2 CHGA
32 cellular ependymoma 29.9 SYP MEN1
33 hyperparathyroidism 29.9 MEN1 CHGA CALCA
34 acromegaly 29.9 SST MEN1 IGF1 GHRH
35 jejunal neoplasm 29.9 SYP ENO2
36 mccune-albright syndrome 29.8 SST MEN1 IGF1
37 hyperinsulinemic hypoglycemia 29.8 SST MEN1 ENO2
38 sclerosing hemangioma 29.8 SYP ENO2 CHGA CALCA
39 lung oat cell carcinoma 29.8 SYP ENO2 CHGA CALCA
40 benign ependymoma 29.7 SYP MEN1 ENO2
41 pulmonary sclerosing hemangioma 29.7 SYP ENO2 CHGA
42 gangliocytoma 29.7 SYP GHRH CHGA
43 gastric ulcer 29.7 VEGFA SST CALCA
44 hypoglycemia 29.6 VEGFA SST IGF1 GHRH
45 thyroid carcinoma, familial medullary 29.6 SST MEN1 CHGA CALCA
46 pituitary adenoma, prolactin-secreting 29.6 SST MEN1 IGF1 CHGA
47 cancer-associated retinopathy 29.6 VEGFA ENO2
48 thymoma 29.6 VEGFA SYP SST ENO2
49 pulmonary neuroendocrine tumor 29.5 SYP SST MEN1 CHGA
50 zollinger-ellison syndrome 29.5 SST NTS MEN1 GHRH CHGA

Graphical network of the top 20 diseases related to Carcinoid Syndrome:



Diseases related to Carcinoid Syndrome

Symptoms & Phenotypes for Carcinoid Syndrome

Human phenotypes related to Carcinoid Syndrome:

58 31 (show all 28)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 episodic abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002574
2 protracted diarrhea 58 31 frequent (33%) Frequent (79-30%) HP:0004385
3 night sweats 58 31 frequent (33%) Frequent (79-30%) HP:0030166
4 erythematous plaque 58 31 frequent (33%) Frequent (79-30%) HP:0025474
5 small intestine carcinoid 58 31 frequent (33%) Frequent (79-30%) HP:0006722
6 intestinal carcinoid 58 31 frequent (33%) Frequent (79-30%) HP:0006723
7 nausea and vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002017
8 heart murmur 58 31 occasional (7.5%) Occasional (29-5%) HP:0030148
9 elevated hepatic transaminase 58 31 occasional (7.5%) Occasional (29-5%) HP:0002910
10 asthma 58 31 occasional (7.5%) Occasional (29-5%) HP:0002099
11 facial telangiectasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0007380
12 increased serum serotonin 58 31 occasional (7.5%) Occasional (29-5%) HP:0003144
13 tricuspid regurgitation 58 31 occasional (7.5%) Occasional (29-5%) HP:0005180
14 palpitations 58 31 occasional (7.5%) Occasional (29-5%) HP:0001962
15 rhinorrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0031417
16 chronic noninfectious lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002730
17 right ventricular failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001708
18 bronchospasm 58 31 occasional (7.5%) Occasional (29-5%) HP:0025428
19 abnormal b-type natriuretic peptide level 58 31 occasional (7.5%) Occasional (29-5%) HP:0031138
20 epiphora 31 occasional (7.5%) HP:0009926
21 myopathy 58 31 very rare (1%) Very rare (<4-1%) HP:0003198
22 paraganglioma 58 31 very rare (1%) Very rare (<4-1%) HP:0002668
23 hepatic necrosis 58 31 very rare (1%) Very rare (<4-1%) HP:0002605
24 lack of bowel sounds 58 31 very rare (1%) Very rare (<4-1%) HP:0030145
25 atypical pulmonary carcinoid tumor 58 31 very rare (1%) Very rare (<4-1%) HP:0030446
26 carcinoid tumor 58 Obligate (100%)
27 increased lacrimation 58 Occasional (29-5%)
28 pulmonary carcinoid tumor 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Carcinoid Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.96 ENO2 GHRH HTR3A NPY NTS PYY
2 growth/size/body region MP:0005378 9.93 CHGA ENO2 GHRH HTR3A IGF1 MEN1
3 homeostasis/metabolism MP:0005376 9.7 CHGA GHRH HTR3A IGF1 MEN1 NPY
4 nervous system MP:0003631 9.44 CHGA ENO2 GHRH HTR3A IGF1 MEN1

Drugs & Therapeutics for Carcinoid Syndrome

Drugs for Carcinoid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 195)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4 61825-94-3 5310940 9887054 6857599 43805
2
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
3
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
4
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
5
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
6 Immunosuppressive Agents Phase 4
7 Anti-Bacterial Agents Phase 4
8 Antibiotics, Antitubercular Phase 4
9 Antifungal Agents Phase 4
10 Cathartics Phase 4
11 Laxatives Phase 4
12
Tranexamic Acid Approved Phase 3 1197-18-8 5526
13
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
15
Ondansetron Approved Phase 3 99614-02-5 4595
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
Bevacizumab Approved, Investigational Phase 3 216974-75-3
18
lanreotide Approved Phase 3 108736-35-2
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
20 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
21 Folate Phase 2, Phase 3
22 Vitamin B9 Phase 2, Phase 3
23 Hemostatics Phase 3
24 Antifibrinolytic Agents Phase 3
25 Coagulants Phase 3
26 Cola Phase 3
27 Liver Extracts Phase 3
28 Dermatologic Agents Phase 3
29 Psychotropic Drugs Phase 3
30 Central Nervous System Depressants Phase 3
31
protease inhibitors Phase 3
32 BB 1101 Phase 3
33 Anti-Anxiety Agents Phase 3
34 Antipruritics Phase 3
35 Antipsychotic Agents Phase 3
36 Tranquilizing Agents Phase 3
37 Anti-Inflammatory Agents Phase 3
38 HIV Protease Inhibitors Phase 3
39 glucocorticoids Phase 3
40 Anesthetics Phase 3
41 Narcotics Phase 3
42 Anesthetics, General Phase 3
43 Analgesics, Opioid Phase 3
44 Adjuvants, Anesthesia Phase 3
45 Anesthetics, Intravenous Phase 3
46 Analgesics Phase 3
47 Antineoplastic Agents, Immunological Phase 3
48 Angiogenesis Inhibitors Phase 3
49 Antibodies, Monoclonal Phase 3
50 Antibodies Phase 3

Interventional clinical trials:

(show top 50) (show all 195)
# Name Status NCT ID Phase Drugs
1 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
2 An Open-label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment Recruiting NCT01789281 Phase 4 Everolimus;Sandostatin LAR Depot
3 Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation A Prospective Interventional Trial of Patients With Neuro-endocrine Tumors With Carcinoid Syndrome Receiving Octreotide LAR Terminated NCT04140409 Phase 4 Sandostatin
4 A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
5 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
6 The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis Unknown status NCT01496196 Phase 3 tranexamic acid;tranexamic acid
7 A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606) Completed NCT02026063 Phase 3 Telotristat etiprate
8 A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Completed NCT02063659 Phase 3 Telotristat etiprate;Placebo
9 A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo Completed NCT00412061 Phase 3 Octreotide;Placebo;Everolimus
10 A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy Completed NCT01677910 Phase 3 Telotristat etiprate;Placebo-matching telotristat etiprate
11 A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome Completed NCT00774930 Phase 3 Lanreotide;Placebo
12 A Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients With Metastatic Carcinoid Tumors Whose Disease-related Symptoms Are Inadequately Controlled by Somatostatin Analogues. Completed NCT00690430 Phase 3 Pasireotide;Octreotide
13 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
14 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
15 Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Everolimus (CABINET) Recruiting NCT03375320 Phase 3 Cabozantinib S-malate
16 Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients Active, not recruiting NCT00569127 Phase 3 Octreotide Acetate
17 A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Active, not recruiting NCT01578239 Phase 3 Octreotide LAR;177Lu-DOTA0-Tyr3-Octreotate
18 Randomized Phase III Clinical Trial of Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome Not yet recruiting NCT04065165 Phase 3 Telotristat Ethyl;Lanreotide
19 A Phase III, Prospective, Multicenter, Randomized, Open, Parallel Group Comparison of Lanreotide Autogel® (90 and 120 mg) Administered by Deep Subcutaneous Injection Every Four Weeks, With Sandostatin LAR Depot (20 and 30 mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months, in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome Terminated NCT00092287 Phase 3 lanreotide Autogel (somatostatin analogue);Sandostatin long acting release (LAR) Depot (somatostatin analogue)
20 Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion Terminated NCT00227136 Phase 3 5-Hydroxy-Tryptamine
21 Carcinoid Tumors After Failure of Somatostatin Analogs: a Randomized Phase III of Octreotide Lutate Peptid Receptor Radionuclide Therapy (PRRT) Versus Interferon α-2b Withdrawn NCT01860742 Phase 3 Interferon alpha-2b;177Lu-DOTATATE
22 A RANDOMIZED PHASE II DOUBLE-BLIND TRIAL OF SUNITINIB VERSUS PLACEBO IN COMBINATION WITH LANREOTIDE IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC MIDGUT CARCINOID TUMORS Unknown status NCT01731925 Phase 2 Lanreotide;Placebo (for sunitinib);Sunitinib
23 A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor Unknown status NCT01175096 Phase 1, Phase 2 RAD001 (everolimus, Afinitor®)
24 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Unknown status NCT02038738 Phase 1, Phase 2 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
25 Phase II Study of Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors Unknown status NCT02455596 Phase 2 Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
26 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Unknown status NCT01237457 Phase 2 177Lu-DOTATATE
27 A Prospective, Randomized Trial of Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas Unknown status NCT00993356 Phase 2 Preoperative lanreotide treatment
28 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
29 A Phase II Study of Protracted Infusional 5-Fluorouracil Plus Alpha Interferon for Advanced Metastatic Carcinoid Completed NCT00002470 Phase 2 fluorouracil
30 A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose-Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Completed NCT01104415 Phase 2 Telotristat etiprate
31 Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers) Completed NCT00027638 Phase 2 thalidomide
32 Phase II Study Of Bevacizumab And PEG Interferon Alpha-2b (PEG Intron) In Patients With Metastatic, Or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
33 A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Ascending, Multidose Study To Determine Safety and Tolerability of Orally Administered LX1606 in Subjects With Symptomatic Carcinoid Syndrome Refractory to Stable-Dose Octreotide Long-Acting Release Depot Therapy Completed NCT00853047 Phase 2 Telotristat etiprate;Octreotide LAR Depot;Placebo
34 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
35 An Open-label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of Twice Daily Dosing of SOM230 in Patients With Metastatic Carcinoid Tumors Completed NCT00088595 Phase 2 Pasireotide (SOM230)
36 Phase II Study of PS-341 in Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
37 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
38 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
39 A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
40 Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
41 A Phase II Study of CCI-779 in Metastatic Neuroendocrine Carcinomas Completed NCT00093782 Phase 2 temsirolimus
42 Phase II Trial of 2-Fluorouracil Recombinant Alpha-2a-Interferon and Intravenous Hydroxyurea With Filgrastim in Patients With Refractory GI Malignancies Grant Application Title: Parenteral Hydroxyurea: A Modulator in Pancreatic Cancer Completed NCT00019474 Phase 2 fluorouracil;hydroxyurea
43 A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
44 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
45 A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
46 A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
47 A Phase 1-2 Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Combination With rhuMAb VEGF (Bevacizumab) in Patients With Locally Advanced or Metastatic Carcinoid Tumors Completed NCT00328497 Phase 2 Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
48 A Phase II Study of Axitinib in Advanced Carcinoid Tumors Completed NCT01435122 Phase 2 Axitinib
49 EPO906 Therapy in Patients With Metastatic Carcinoid Tumors and Other Neuroendocrine Tumors Completed NCT00050349 Phase 2 EPO906 epothilone B
50 Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed NCT02575300 Phase 2 Ibrutinib

Search NIH Clinical Center for Carcinoid Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Interferon Alfa-2b

Genetic Tests for Carcinoid Syndrome

Anatomical Context for Carcinoid Syndrome

MalaCards organs/tissues related to Carcinoid Syndrome:

40
Heart, Lung, Liver, Pituitary, Small Intestine, Appendix, Thyroid

Publications for Carcinoid Syndrome

Articles related to Carcinoid Syndrome:

(show top 50) (show all 2107)
# Title Authors PMID Year
1
Cost-of-illness of metastatic gastroenteropancreatic neuroendocrine tumours in Sweden-A population-based register-linkage study. 61 42
30652364 2019
2
The utility of 18F-FDG and 68Ga-DOTA-Peptide PET/CT in the evaluation of primary pulmonary carcinoid: A systematic review and meta-analysis. 42
30855482 2019
3
Sclerosing pneumocytoma mixed with a typical carcinoid tumor: A case report and review of literature. 42
30702609 2019
4
Anesthesia for Endocrine Emergencies. 61
32008649 2020
5
Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis. 61
32032719 2020
6
Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia. 61
31605174 2020
7
Must antidepressants be avoided in patients with neuroendocrine tumors? Results of a systematic review. 61
32036806 2020
8
Inhibition of serotonin synthesis: A novel therapeutic paradigm. 61
31629717 2020
9
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. 61
31987306 2019
10
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study. 61
31406974 2019
11
Description of a transient proximal tubulopathy induced by amino acids perfusion in peptide receptor radionuclide therapy: A case report. 61
31876733 2019
12
Multidisciplinary team management of carcinoid heart disease. 61
31751305 2019
13
Direct costs of carcinoid syndrome diarrhea among adults in the United States. 61
31885426 2019
14
TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World. 61
31189618 2019
15
Carcinoid Heart Disease: A Guide for Clinicians. 61
31587790 2019
16
Carcinoid Heart Disease: a Comprehensive Review. 61
31745664 2019
17
Idiopathic anaphylaxis. 61
31690394 2019
18
The Outcome of Primary Hepatic Neuroendocrine Tumors: A Single-Center Experience. 61
31889752 2019
19
[Current standards and novel developments in the treatment of neuroendocrine tumors of the gastroenteropancreatic system]. 61
31594011 2019
20
Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors. 61
31593022 2019
21
Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors. 61
31015313 2019
22
Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. 61
31655936 2019
23
Primary neuroendocrine tumour of the left ventricle. 61
31562505 2019
24
Management of Diarrhea in Patients With Carcinoid Syndrome. 61
31425482 2019
25
Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues. 61
31326125 2019
26
Management of Small Bowel Neuroendocrine Tumors. 61
31540509 2019
27
Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE. 61
31414209 2019
28
Hedinger syndrome: first experience and two-year follow-up in patients with carcinoid heart disease. 61
31559025 2019
29
Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. 61
31448649 2019
30
Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. 61
30651397 2019
31
Generalized Cytokine Increase in the Setting of a Multisystem Clinical Disorder and Carcinoid Syndrome Associated with a Novel NLRP12 Variant. 61
30788684 2019
32
Inhibition of Serotonin Synthesis May Have Antitumor Activity? Long-Term Efficacy in a Patient with Gastrointestinal Neuroendocrine Tumor. 61
30877189 2019
33
LARGE CELL METASTATIC PANCREATIC NEUROENDOCRINE CARCINOMA TREATED WITH SOMATOSTATIN ANALOGUES - CASE REPORT AND LITERATURE REVIEW. 61
32010361 2019
34
Evidence-Based Policy in Practice: Management of Carcinoid Syndrome Diarrhea. 61
31258314 2019
35
Improving outcome of valve replacement for carcinoid heart disease. 61
30527716 2019
36
Paraneoplastic syndromes and other systemic disorders associated with neuroendocrine neoplasms. 61
30910348 2019
37
Efficacy of the tryptophan hydroxylase inhibitor telotristat on growth and serotonin secretion in 2D and 3D cultured pancreatic neuroendocrine tumor cells. 61
31319410 2019
38
Trabecular carcinoid tumor arising from a mature cystic teratoma. 61
31258297 2019
39
Idiopathic anaphylaxis. 61
31002196 2019
40
Assessment of appendix carcinoid tumors: A retrospective study. 61
31361229 2019
41
Carcinoid Syndrome: Updates and Review of Current Therapy. 61
31286272 2019
42
Early Outcomes of Surgery for Carcinoid Heart Disease. 61
31383543 2019
43
Telotristat ethyl for carcinoid syndrome diarrhoea. 61
31363315 2019
44
The path to surgery in carcinoid heart disease: a retrospective study and a multidisciplinary proposal of a new algorithm. 61
29914291 2019
45
Predicting human disease mutations and identifying drug targets from mouse gene knockout phenotyping campaigns. 61
31064765 2019
46
A case of pseudocystic liver metastases from an atypical lung carcinoid tumor. 61
30891110 2019
47
Efficacy of Detoxsan® powder on diarrhea caused by gastrointestinal neuroendocrine tumors. 61
31114139 2019
48
A 'Bit' of Appendicitis: A Case of a Foreign Object in the Adult Appendix. 61
31363433 2019
49
Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. 61
30355775 2019
50
A Case of Primary Ovarian Insular Carcinoid Tumor Presenting with Carcinoid Syndrome. 61
30956498 2019

Variations for Carcinoid Syndrome

ClinVar genetic disease variations for Carcinoid Syndrome:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SDHD NM_003002.4(SDHD):c.149A>G (p.His50Arg)SNV Conflicting interpretations of pathogenicity 6909 rs11214077 11:111958677-111958677 11:112087953-112087953

Expression for Carcinoid Syndrome

Search GEO for disease gene expression data for Carcinoid Syndrome.

Pathways for Carcinoid Syndrome

GO Terms for Carcinoid Syndrome

Cellular components related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 VEGFA SST PYY NTS NPY IGF1
2 terminal bouton GO:0043195 9.33 SYP GHRH CALCA
3 extracellular space GO:0005615 9.32 VEGFA SST PYY NPY IGF1 IFNA2

Biological processes related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.93 SST PYY NTS NPY GHRH CALCA
2 neuropeptide signaling pathway GO:0007218 9.61 PYY NPY CALCA
3 cell-cell signaling GO:0007267 9.56 SST IFNA2 GHRH CALCA
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.5 VEGFA IGF1 IFNA2
5 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.4 IGF1 GHRH
6 intestinal epithelial cell differentiation GO:0060575 9.37 PYY NPY
7 regulation of blood pressure GO:0008217 9.33 NPY CHGA CALCA
8 response to heat GO:0009408 9.13 SST IGF1 CALCA
9 feeding behavior GO:0007631 8.8 PYY NPY CALCA

Molecular functions related to Carcinoid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.35 SST PYY NPY IGF1 CALCA
2 neuropeptide hormone activity GO:0005184 8.92 PYY NTS NPY GHRH

Sources for Carcinoid Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....